We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
Clinical Biochemistry 2008 July
OBJECTIVES: In this study, we aimed to investigate the activities of paraoxonase-1 (PON1) and nitric oxide synthase (NOS) and the levels of asymmetric dimethylarginine (ADMA), nitric oxide (NO), oxidized low-density lipoprotein (oxLDL), ceruloplasmin (CP), thiobarbituric acid-reactive substances (TBARS), malondialdehyde (MDA), 4-hydroxynonenal (HNE) and lipids in serum of patients with end-stage renal disease (ESRD) having continuous ambulatory peritoneal dialysis (CAPD) treatment and controls living in the Antalya region, Turkey.
DESIGN AND METHODS: Fifty-three patients with ESRD were enrolled in this study and were treated by CAPD. As the control group (n=32), subjects with normal renal function were included.
RESULTS: Serum PON1 activity and high-density lipoprotein-cholesterol (HDL-C) levels were decreased in ESRD patients whereas ADMA, NO, oxLDL, CP, TBARS, MDA and HNE levels and NOS activity were increased with regard to control group. In CAPD patients, ADMA positively correlated with NO, CP, oxLDL, TBARS and MDA levels whereas negatively correlated with PON1 activity. On multiple logistic regression analysis, risk factors associated with ESRD included CP, TBARS, triglycerides (TG) and very low-density lipoprotein-cholesterol (VLDL-C) levels.
CONCLUSIONS: Our data have demonstrated that ESRD patients on CAPD treatment exhibit increased lipid peroxidation reactions and decreased antioxidant protection. The assay of serum HNE and MDA may be useful to evaluate the individual accumulation of these toxic aldehydes to test the efficiency of new dialysis strategies in removing them.
DESIGN AND METHODS: Fifty-three patients with ESRD were enrolled in this study and were treated by CAPD. As the control group (n=32), subjects with normal renal function were included.
RESULTS: Serum PON1 activity and high-density lipoprotein-cholesterol (HDL-C) levels were decreased in ESRD patients whereas ADMA, NO, oxLDL, CP, TBARS, MDA and HNE levels and NOS activity were increased with regard to control group. In CAPD patients, ADMA positively correlated with NO, CP, oxLDL, TBARS and MDA levels whereas negatively correlated with PON1 activity. On multiple logistic regression analysis, risk factors associated with ESRD included CP, TBARS, triglycerides (TG) and very low-density lipoprotein-cholesterol (VLDL-C) levels.
CONCLUSIONS: Our data have demonstrated that ESRD patients on CAPD treatment exhibit increased lipid peroxidation reactions and decreased antioxidant protection. The assay of serum HNE and MDA may be useful to evaluate the individual accumulation of these toxic aldehydes to test the efficiency of new dialysis strategies in removing them.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app